From the president-elect's seminar to the explosion of the world, listen to WCLC President Professor Wu Yilong talk about a new breakthrough in the treatment of thoracic mesothelioma.

Under the influence of the new crown epidemic, in order to avoid large-scale gathering of people, this year's major international cancer-related academic conference organizers have taken cancellation, regular or irregular extension, online virtual meetings and other ways to deal with the impact of the outbreak.
the 21st World Lung Cancer Congress (WCLC 2020), hosted by the International Lung Cancer Research Association (IASLC), was no exception, with the congress scheduled for August 9-12 in Singapore earlier announcing that it would be postponed until 28-31 January 2021 through the virtual conference line.
, unlike other postponed academic meetings, WCLC held an online chair seminar (IASLC WCLC 2020 Virtual Presidential Symposium) on August 8.
has been postponed, why should we advance the Chairman's Seminar? With this question in mind, the author consults Professor Wu Yilong, President of the WCLC 2020 General Assembly and Life Director of Guangdong Provincial People's Hospital.
Wu Yilong, Chairman of the 2020 World Lung Cancer Congress (WCLC), Lifetime Director, Guangdong Provincial People's Hospital, Professor of Oncology, Doctoral Mentor, Winner of the IASLC Distinguished Science Award, Global HighLy Cited Scientist in Clinical Medicine 2018-2019, Honorary Director of Guangdong Lung Cancer Research Institute (GLCI) Director, Director of the Key Laboratory of Lung Cancer Translational Medicine in Guangdong Province, Chairman of the Oncology Department of the Wu Tianping Foundation, Vice Chairman of the Precision Medicine Committee of the Chinese Physicians Association, President of the Guangdong Clinical Trials Association (GACT), Chairman of the China Chest Tumor Research Collaboration Group (CTONG), Chairman of the Lung Oncology Society of the Guangdong Medical Association, Former Chairman of the Chinese Society of Clinical Oncology, and now Chairman of the Steering Committee.
a trial that will change clinical practice", the importance of judging a clinical trial is whether it can change our clinical practice.
Professor Wu Yilong revealed that the original WCLC 2020 Chairman's Seminar is scheduled to be held in January next year, the same as the main meeting, "but in this WCLC's many contributions, we found that the results of several clinical studies are very prominent, should be announced to industry counterparts as soon as possible."
we are discussing a dedicated online chair seminar in August to announce these heavyweight results.
Professor Wu said that the selection process for abstracts is very strict, and the committee will invite relevant experts to rate the contribution lBA's multiple research abstracts blindly, and then summarize them, with the Chairman's Meeting to assess the significance of the study, its impact on clinical practice, whether it is broadly representative, and so on, before selecting the report to be presented at the Chairman's Seminar.
in all the reports submitted, the CheckMate-743 study of Navuliyu monoantigen monoantigen for the treatment of advanced malignant thoracic mesothelioma (MPM) attracted great attention from the review team.
if the study were to yield positive results, it would have a significant impact on the clinical practice of malignant thoracic mesothelioma.
"" WCLC 2020 General Assembly President Professor Wu Yilong said, "In fact, CheckMate-743 did not live up to expectations, in a number of research abstracts stand out, and become the President's seminar published in the three most enthusiastic response to the study."
" as a rare and highly invasive malignancy that grows along the thoracic membrane, the incidence of MPM is highly corred with asbestos exposure.
most patients have been delayed in diagnosis and the disease has progressed or metastasis at the time of diagnosis.
the prognosis of malignant thoracic mesothelioma is generally poor, and at the beginning of chemotherapy drugs, the objective remission rate (ORR) was only 4%-15%, which was not satisfactory.
it was not until 2004 that the combined use of pemite and platinum increased the therapeutic remission rate of MPM, but the patient's survival period was still not significantly extended.
data show that patients with untreated advanced or metastasis MPM have a medium survival of less than one year and a five-year survival rate of less than 10%.
and no new systemic treatments have been approved for more than 10 years since the approval of first-line treatment in 2004.
The results of the CheckMate-743 trial, published this time, confirmed that Navuliyu monoantigen ipimu monoantigen can significantly improve the total survival of patients with previously untreated, non-removable malignant thoracic mesothelioma (OS), which is a major breakthrough in the treatment of MPM.
it is understood that the results of the study after the release of a wide range of industry discussions, a number of international lung cancer experts commented that malignant thoracic mesothelioma ushered in a major breakthrough, is expected to change the future of clinical treatment decisions.
the general direction of reducing chemotherapy" currently has a clinical trend for chest tumors, including MPM - minimizing chemotherapy and even avoiding chemotherapy in the first line.
" In the view of Professor Wu Yilong, President of the WCLC 2020 General Assembly, immunotherapy programmes are also tending to be low-dose, long intervals, less chemotherapy or even no chemotherapy.
" and CheckMate-743 was the first first line of treatment for thoracic mesothelioma to be compared head-to-head with chemotherapy.
"CheckMate-743 is designed to assess the therapeutic effects of Narvulyu monoantigen monoantigen for patients with previously untreated malignant thoracic mesothelioma (MPM; n-605) compared to standard chemotherapy (Pemetroser combined cisplatin or carptonine).
In this clinical study, 303 patients were treated with navuliyu monoanti (3mg/kg) every two weeks and Ipimu monoanti (1mg/kg) every six weeks for a maximum duration of 24 months, or until the disease progressed or be impatient.
302 patients were treated with cisplatin (75 mg/m2) or carptin (AUC 5) in a 21-day cycle, which lasted six cycles until the disease progressed or beedible to toxicity.
end point of the trial was the total lifetime (OS) of all randomized grouped patients, and the key secondary endpoints included objective mitigation rate (ORR), disease control rate (DCR), and progress-free lifetime (PFS).
The survival curve of the CheckMate-743 study, which was published at the WCLC 2020 Chair's Workshop on August 8, confirmed that Navuliyu monoantigen combined with epipenine monoantigen significantly improved the total survival of patients with previously untreated, non-removable malignant thoracic mesothelioma (OS).
in Professor Wu Yilong's view, PD-1 single-anti-joint CTLA-4 single-resistance has a synergistic mechanism, two-pronged can play a better effect.
and the CheckMate-743 did not go out of their sights.
results suggest that combined therapy can reduce the risk of death by 26% at a minimum of 22 months of follow-up, which is a great bright spot for MPM clinical treatment.
, the patient's medium OS was 18.1 months, while the chemotherapy group was 14.1 months.
" CheckMate-743 increased OS by four months, which is a very good result for highly invasive malignancies.
" Regardless of histological type, there is another bright spot in the Phase III clinical study of CheckMate-743, published this time: patients with non-epithelial and epithelial mesothelioma treated with Navuliyu monoantigen monotherapy have improved survival and have seen greater benefits in the subgroups of non-epithelial patients.
In the biimmune combination therapy group, the mesothentic OS in the upper and non-corted patients was 18.7 months and 18.1 months, respectively, while in the chemotherapy group, the mesos in the corresponding patients were 16.5 months and 8.8 months respectively (upper-skin subgroup HR: 0.86 (95% CI: 0.69, 1.08? Non-skin subgroup HR: 0.46 (95% CI: 0.31, 0.68) ). Professor OS Wu Yilong of the
epithelitis MPM subgroup (left) and non-epithelat MPM subgroup (right) points out that in the past histological types were recognized as prognosis factors for malignant pleural mesothelioma, and that non-epithelat type usually has a worse prognosis, while CheckMate-743 confirms that patients with non-epithelitis in the biimmune programme benefit more, suggesting that immunotherapy may have greater potential for this group of patients.
considering the long-term tailing effects of double immunotherapy in other tumors, Professor Wu Yilong is also confident of the long-term survival of double immunotherapy in the field of MPM.
is expected to be a major advantage of the new standard immunotherapy for MPM first-line treatments: once effective, sustainability tends to be better, as demonstrated again in the CheckMate-743 study.
in the evaluation of the efficacy of tumor remission, it is worth noting that dual immunotherapy showed lasting efficacy, with the duration of in-place remission (mDoR) extended to nearly twice that of the chemotherapy group to 11.0 vs 6.7 months.
long-term follow-up results showed that about one-third (32%) of patients who were first assessed for remission using dual immunotherapy had a duration of 2 years, compared with 8% in the chemotherapy group.
results from the CheckMate-743 study are noteworthy that immunotherapy options have shown a high degree of safety in several clinical studies after continuous optimization and adjustment.
the study, the safety of Navuliyu monoantigen monoantigen was consistent with previously reported findings and no new safety signals were observed.
" In dual immunotherapy, the dose of Ipimu monoantigen was adjusted from the regular 3mg/kg to 1mg/kg, and the life cycle was extended from once every 3 weeks to once every 6 weeks, while ensuring efficacy, safety was also taken into account.
" based on CheckMate-743 research data, The dual immunotherapy program of Navuliyu monoantigen-combined Ipimu monoimmune is likely to become a new standard for first-line treatment of MPM.
" on the future development, Professor Wu Yilong stressed that CheckMate-743 dual immunotherapy program, the current domestic only PD-1 inhibitor Navuliyu monoanti, the urgent need to speed up the CTLA-4 inhibitor Ipimu monoantigen market, otherwise for MPM patients, the new treatment strategy of dual immunity will become a castle in the sky, it is difficult to have real benefits.
In addition, as there are currently no immuno-oncology drugs approved in Chinese mainland for the treatment of pletrial mesothelioma, Professor Wu Yilong cautioned that in addition to the urgent need to address the problem of drug availability, clinical needs to accumulate more experience in the diagnosis and treatment of rare and highly invasive malignancies, and in the next step to consider exploring the application of dual immunotherapy in many other tumors.
It is worth noting that the current Navuliyu monoantigen ipimu monoantigen has shown clinical benefits in six different tumor species, including a sustained and significant survival benefit that is superior to chemotherapy for two of these breast tumors.
Immune Time Source: Biological Exploration Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.